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PART 1 
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ANATOMY 
        Ocular surface comprises of cornea, conjunctiva and limbus. The 
conjunctiva extends from mucocutaneous junction of the lids to the 
limbus . It can be divided into 3 geographic zones: palpebral, fornical, 
and bulbar .  
“The palpebral conjunctiva starts at the mucocutaneous junction of the 
eyelid and it covers the inner surface eyelid. This part of conjunctiva 
attaches firmly to the tarsus”.  
“The delicate bulbar conjunctiva is freely movable over the globe 
but fused with the Tenon’s capsule and gets inserted into the limbus”.  
“The conjunctival tissue becomes superfluous and freely movable in the 
fornices (forniceal conjunctiva), where it gets enmeshed with the fibrous 
elements of levator aponeurosis and Muller’s muscle of the upper eyelid. 
And in the lower eyelid fibrous extensions of the inferior rectus muscle 
fuse with the inferior tarsal muscle”.  
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The conjunctiva is a mucous membrane lined with non keratinizing 
squamous epithelium with numerous goblet cells and a thin highly 
vascularized substantia propria containing lymphatic vessels, plasma 
cells, macrophages and mast cells. A lymphoid layer extends from the 
bulbar portion of conjunctiva to the sub tarsal folds of the eyelids. In 
places specialized aggregations of conjunctiva-associated lymphoid tissue 
(CALT) corresponding to the mucosa associated lymphoid tissue (MALT) 
elsewhere and contains collections of T and B lymphocytes lying 
underneath a modified epithelium. These regions are supposed to be 
concerned with antigen processing.  
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The thickness of the conjunctival epithelium varies from 2 to 5 
cells size. The basal cells of the conjunctival epithelium are cuboidal and 
progress into flattened polyhedral cells as they reach the conjunctival 
surface. Goblet cells (unicellular mucous glands) are seen concentrated 
near the inferior and medial portions of the conjunctiva, especially in the 
region of the plica semilunaris and caruncle. Goblet cells are sparsely 
distributed throughout the remaining portion of the conjunctiva and are 
absent in the limbal region. 
 
 
 
 
 
 
 
 
 
The conjunctiva reflects on three sides to form a fornix. Medially 
plica semilunaris is situated. The loose conjunctiva in this area allows for 
free movement of the eyelids and the eyeball. Conjunctival folds decrease 
the surface area of contact, increasing its surface area, and decrease 
contact between the tarsal and bulbar conjunctiva.  
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PARTS OF CONJUNCTIVA 
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Superior fornix being larger and is formed by smooth muscle strips 
extending from the lower part of levator palpebrae muscle to get inserted 
into the conjunctiva. Thus during upward gaze it prevents the superior 
fornix of conjunctiva from moving down and obscuring vision.  
“Temporal conjunctiva gets attached to lateral rectus tendon by 
fine fibrous strips which maintains its position during horizontal gaze. 
Except in adduction there is no true fornix medially. Fibrous strips from 
the tendon of medial rectus get inserted into the caruncle and plica 
semilunaris. When medial rectus contracts during adduction of eye, a cul-
de-sac is formed medially when these slips contracts”. The surface area of 
each eye of adult conjunctiva including cornea averages about 16 cm2.  
“Plica semilunaris is a semi lunar- shaped fold of conjunctiva 
whose outer border lies 3–6 mm lateral to conjunctival caruncle. A cul-
de-sac of 3 mm depth is formed on adduction that obliterate when the eye 
abduct. Goblet cells are found in conjunctival epithelium, it also consists 
of langerhans cells, dendritic melanocytes”.  
“The substantia propria is a highly vascular structure and it may 
contain smooth muscle fibres, sympathetic nerves, fatty tissue, and 
cartilage”.  
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In the interpalpebral fissure caruncle is located medially measures 
horizontally 4 mm and 3mm vertically. It is joined  to the medial rectus 
muscle and goes along with plica while  moving the eyeball. It is contains 
accessory lacrimal gland , pilosebaceous units, eccrine glands and few  
non striated muscle fibres. Sometimes in the deeper portion of the 
caruncle lots of  large sebaceous glands  may be noted  like meibomian 
glands.  
“In the  mucocutaneous junction of the lid margin epithelium 
changes  from keratinized stratified squamous epithelium to the non 
keratinized stratified squamous epithelium”.  
“Meibomian glands  appears as yellow round forms  that are 
secluded  by blood vessel  arches of  tarsal plate of the upper and lower 
eyelids running perpendicular to the lid margin”.  
Hydrophobic strip of lipid seperates the nonkeratinized portion of 
the lid from keratinized part. These lipids are produced by the meibomian 
glands lying over  mucocutaneous junction.  
Position of mucocutaneous junction is determined by tear film 
meniscus air–fluid border . “The mucocutaneous junction will move 
anteriorly in case of entropion and the mucocutaneous junction will move 
posteriorly in case of ectropion” .  
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The anterior corneal surface have a smooth surface due to tarsal 
conjunctiva being strongly attached to tarsal plate. Subconjunctival tissue 
plane is not available for dissection in the tarsal conjunctiva. A shallow 
subtarsal groove is present posterior to the lid margin along the tarsal 
surface which is less than 1-mm in depth.  
 
“In this region the nonkeratinized squamous epithelium of lid 
margin get transformed into cuboidal epithelium of the tarsal part of 
conjunctiva” 
 
In between tarsal groove and eyelid margin there are many grooves 
and ridges which communicates to the invagination surfaced with goblet 
cells of the conjunctiva. Few of these crypts are seen since childhood and 
many of them develops at the time of puberty. “Above the age of 50 years 
these crypts are identified in about one-third of conjunctival specimens. 
Crypts are usually more in number closer to the medial portion of the 
conjunctiva and in the region of plica semilunaris”. 
 
 “Glands of wolfring is seen in the palpebral conjunctiva and 
Glands of  Krause is found in forniceal conjunctiva ”. 
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Bulbar conjunctiva receives blood supply from the Anterior ciliary 
arteries. The tarsal conjunctiva receives blood supply from the branches 
of the marginal arcades of the eyelids. The proximal arterial arcade 
running along the upper border of the eyelid as the posterior conjunctival 
arteries, send branches proximally to supply the fornical and then the 
bulbar conjunctiva.  
 
The Limbus receives blood supply from the ciliary arteries through 
the anterior conjunctival arteries. Vascular watershed between the 
anterior and posterior vascular territories lies approximately 3 or 4 mm 
from the limbus. 
 
The innervation of the conjunctiva is derived from the ophthalmic 
division of  Trigeminal nerve. 
 
CORNEA 
Cornea is a transparent avascular watch glass like structure which 
is lined by stratified squamous epithelial cells which is about 50-90µm in 
thickness and contains 5-6 layers of cells.  
Limbal basal layer contains corneal epithelial stem cells. The 
corneal epithelial stem cells proliferate continuously to form the 
superficial layer and it changes to form superficial cells.  
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The air- tear interface at the surface of cornea forms a positive lens 
of approximately 43 diopters (D) and constitutes the main refractive 
factor of the eye. The central third of the cornea measures about 4 mm in 
diameter in the normal eye and is nearly spherical. As the posterior 
surface of the cornea is more curved than the anterior surface, the central 
cornea is much thinner (0.5 mm) than the peripheral cornea (1.0 mm). 
 
The cornea gets flatter near the periphery but the rate of flattening 
is not symmetrical. Corneal flattening is more widespread nasally and 
superiorly than temporally and inferiorly. This topography is more 
important when fitting a contact lens.  
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The anterior surface of cornea is derived from surface ectoderm 
and is lined by nonkeratinising stratified squamous epithelium whose 
basal columnar layer by hemidesmosomes gets attached to a basal lamina. 
The basal cells of cornea have a width of about 12 µm and a density of 
approximately 6000 cells/mm2.  
 
Improper formation of hemidesmosomes after an epithelial 
abrasion may contribute to the occasional recurrence of corneal erosion 
following a traumatic corneal abrasion. 2 or 3 layers of polygonal "wing" 
cells overlie the basal cell layer.  
 
The superficial corneal epithelial cells are extremely thin (30 µm) 
and get binds to one another by zonules. These zonules give the 
properties of a semipermeable membrane to the corneal epithelium. 
Microvilli and Microplicae makes the superficial surfaces of the wing 
cells highly irregular, but the precorneal tear film makes the corneal 
surface optically smooth.  
 
Although the deeper epithelial cells are strongly attached to one 
another by desmosomes, they migrate constantly from the basal region 
towards the tear film, where they are shed. They also migrate from their 
stem cell source at the limbus centripetally.  
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Diffuse damage to the limbal stem cells (chemical burns, 
trachoma) leads to chronic epithelial surface defects. Division of the 
slow-cycling stem cells at the limbus gives rise to a progeny of daughter 
cells (transient amplifying cells), whose division helps to maintain the 
integrity corneal epithelium.  
 
LIMBUS 
Limbus is the transition zone between the peripheral cornea and the 
anterior sclera. Though it is not a distinct anatomical structure, the limbus 
is important for two reasons:  
 1) Its relationship to the chamber angle and  
 2) It acts as a surgical landmark.  
The following structures are included in the limbus:  
 
 Conjunctiva and limbal palisades 
 Corneoscleral stroma 
 Tenon capsule 
 Episclera 
 Aqueous outflow apparatus 
 
The transition from opaque sclera to clear cornea is difficult to 
define histologically and it occurs gradually over 1.0-1.5 mm area. The 
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sclerocorneal junction begins centrally in a plane linking the end of 
Bowman's layer and the Schwalbe’s line. Internally posterior limit of 
sclerocorneal junction is the anterior tip of the scleral spur. The surgical 
limbus can be divided conceptually into 2 equal zones:  
I) Anterior bluish gray zone lying over clear cornea extending from 
Bowman's layer to the Schwalbe’s line  
2) A posterior white zone lying over the trabecular meshwork, extending 
from the Schwalbe’s line to the scleral spur or iris root.  
Familiarity with these landmarks is important to the surgeon performing 
cataract surgery or a glaucoma- filtering operation. 
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INTRODUCTION 
 
“In 1995 LEE and HIRST first coined the word Ocular Surface 
Squamous Neoplasia (OSSN)”.  
 
It consists of a spectrum of neoplasm that originates from the 
conjunctival limbal stem cells and extends beyond the limbus to involve 
the adjacent cornea and conjunctiva, varies from “simple dysplasia to 
more invasive squamous cell carcinoma”. Ocular Surface Squamous 
Neoplasia is a localised slow growing neoplasm which has a low 
metastatic potential but invasive type of lesion can locally invades into 
the eyeball and the orbital cavity. Death results if the invasive tumour 
goes untreated. Ocular Surface Squamous Neoplasia has a high 
recurrence rate even following management.  
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OSSN is a rare ocular tumour, first most common being melanoma 
and second common being lymphoma and OSSN comes after these two 
tumours. Prevalence of OSSN is more near the equator and possibly 
related to sunlight exposure. Prevalence is more common in males and 
Caucasian race. It occurs most commonly in the age group of 50-60 
years, but also more common in patients lesser than 50 years of age living 
close to equator. 
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ETIOLOGIC FACTORS 
1. Ultraviolet irradiation  
2. HPV infection.  
The above two being the most common cause 
OTHER RISK FACTORS 
1. HIV positivity, 
2. Immunosuppression,  
3. Old age,  
4. Male sex,  
5. Fair skin,  
6. Smoking,  
7. Exposure to petroleum products, 
8. Vitamin A deficiency,  
9. Exposure to chemicals such as trifluridine and arsenicals, 
10. Xeroderma pigmentosum, 
11. European ancestry, 
12. Long standing use of ocular prosthesis and contact lens wear.  
13. Exposure to dust, 
14. Ocular trauma 
15. Pinguecula 
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16. Pterygium 
17. Solar keratosis. 
UV-B RADIATION 
Evidence from epidemiological studies have showed that the 
incidence of  OSSN was found to be increased in population living in 
proximity to the equator due to increased exposure to solar UV radiation.  
For each 10 degree rise in latitude the occurrence of carcinoma 
decreases by 40-50%. Limbus being the most common area for 
development of tumour as the inter palpebral area is highly exposed to 
sunlight. Dysplasias are more common in limbus as the squamous and 
columnar epithelium meets at the limbus.  
Risk for developing OSSN depends on the intensity of exposure, 
type of UV rays, total cumulative exposure and the magnitude of the 
light-absorbing ‘‘protective mantle’’ of melanin. “The UV portion of the 
solar spectrum can be subdivided into three wavelength ranges: UVA 
(320–400 nm), UVB (280–320 nm), and UVC (200– 280 nm)”. Of these 
three forms UVB is believed to be responsible for inducing various 
cutaneous and ocular surface malignancies. 
Exposure to UVB light causes  
1) Formation of pyrimidine dimers in DNA. 
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2) Damage to the nucleotide excision repair pathway (which plays 
an important role in repairing the DNA damage caused by UV-B 
exposure).  
3) Unrepaired alterations in the DNA are the essential step in the 
process of   initiation of malignant transformation. 
4) UV radiation is known to cause mutations in tumour suppressor 
genes like p53 
These alterations become heritable once these altered and injured 
DNA undergoes a cycle of proliferation, this stimulus to the proliferation 
could be provided by the UV rays themselves or by virus such as HPV or 
some chemical stimulus. An altered pattern of expression of  MMP-1 and 
MMP-3, following ultraviolet B radiation is responsible for the 
development of OSSN in a study published in 2008 regarding the role of 
matrix metalloproteinases (MMP) and tissue inhibitors of matrix 
metalloproteinases in the development of OSSN (Ng et al. 2008) 
HUMAN PAPILLOMA VIRUS: 
The reason for the development of OSSN in those affected with 
HPV is not clear. About 50% of the squamous cell carcinoma of the 
cornea, conjunctiva, limbus and lacrimal sac were linked to the infection 
with Human papilloma virus (Nakamura et al. 1997).  
 18 
 
“HPV 16 & 18 DNA were demonstrated in high grade OSSN and 
invasive type of OSSN (Verma et al. 2008, Sjo et al. 2007)”. HPV 6 & 11 
were found to be associated with the causation of conjunctival papilloma 
(Nakamura et al. 1997). It is stated that additional risk factor like 
exposure to ultra violet irradiation is needed for the causation of tumour.  
“One study found out the DNA of Human Papilloma Virus 16, 18 
and mRNA of  Human Papilloma Virus noted in  E6 region, and it 
denotes the transcribed form of viruses from the samples of patients with 
CCIN by using the Polymerase Chain Reaction method (Scott et al. 
2002)”.  
HUMAN  IMMUNODEFICIENCY  VIRUS: 
At present OSSN is considered as an HIV associated malignancy. 
In Africa following a huge pandemic of HIV infection there is an increase 
in the number of cases of OSSN. A case control study to demonstrate the 
relationship of conjunctival squamous cell carcinoma and HIV infection 
demonstrated a 10 fold increased risk in HIV infected individuals in 
Uganda (Waddell et al. 1996). The risk was found to be highest in 
patients with age ≥ 50 years and in those who are exposed to high 
ultraviolet irradiation.  
In those infected with HIV infection the disease is more aggressive 
and also seen in younger age group requiring enucleation or even 
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exenteration (Newton et al. 2002). “OSSN specimens from HIV infected 
individuals showed multiple oncogenic viruses like HPV, KSHV, EBV 
suggesting these viruses may also responsible for the occurance OSSN 
(Simbiri et al. 2010)”. Several studies reported that OSSN considered is 
as the first clinical presentation of  HIV in younger patients.  
IMMONOSUPPRESSION 
Those who undergo corneal grafting the development Ocular 
Surface Squamous Neoplasia is related to local immunosuppression.  
“Human Papilloma Virus or neoplastic cells from the donor’s corneal 
epithelial cells may leads to the development of OSSN if they are present 
in the graft (Ramasubramanian et al. 2010)”. 
XERODERMA PIGMENTOSUM 
Xeroderma pigmentosum (XP) is an autosomal recessive disorder, 
with defective mechanism of DNA repair. It can predispose to Ocular 
Surface Squamous Neoplasia and other cutaneous and mucosal cancers 
with an aggressive presentation even at a younger age. A patient of 
Xeroderma Pigmentosum was reported to have OSSN as early as 3 years 
of age. In a study conducted at National Eye Institute with 87 participants 
having Xeroderma Pigmentosum ,10% of the patients in age range 5–28 
years with Xeroderma Pigmentosum had ocular surface cancers. 
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OTHER RISK FACTORS 
Ocular injury and exposure to dust particals were also implicated 
as a possible risk factors in the development Ocular Surface Squamous 
Neoplasia, but there are only few reports supporting this fact based on 
few case studies. There is an increased risk associated with a report of 
prior trauma to the affected eye; which was first established in an 
observational study. As the precise nature of the previous eye injury was 
not available it was relevant only in about 8% of cases. 
“In 1979 Clear et al. analysed 234 conjunctival biopsies and 
identified that pinguecula, solar keratosis and pterygium represents a 
continuous spectrum of the same pathological event finally leading to 
carcinomatous change”. 
 Evidence relating to the nature of the association between exposure to 
solar UV and development of pinguecula and to a lesser extent pterygium 
is relatively sparse.  
“In around 98% of cases having clinically identified pinguecula in 
the contra-lateral eye developed OSSN thus stating the association 
between the presence of pinguecula and risk of OSSN”. But in those with 
pterygium development of OSSN was relatively rare in both cases and 
controls and thus revealing that there is no association between pterygium 
and OSSN. 
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CLINICAL MANIFESTATIONS 
Primary tumours of the cornea and conjunctiva can be classified 
into two groups: congenital tumours and acquired tumours. Tumours 
arising from squamous epithelial cells, melanocytes & lymphocytes are 
included under the group of acquired lesions.  
Ocular Surface Squamous Neoplasia are classified into  
“Benign type contains lesions like conjunctival Papilloma, 
Pseudoepitheliomatous hyperplasia and hereditary intraepithelial 
dyskeratosis”.  
Preinvasive- in this the lesions are limited to the epithelium which can be 
classified as mild CCIN, Moderate CCIN, Severe CCIN 
Squamous cell carcinoma comes under invasive type of Ocular 
Surface Squamous Neoplasia in which the epithelial basement membrane 
is breached by tumour cells.  
 Another aggressive variant of OSSN is Mucoepidermoid 
carcinoma. 
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CONJUNCTIVAL PAPILLOMA 
Conjunctival papilloma can be divided into sessile, pedunculated 
type . Pedunculated form contains a stalk which is formed by a fibro 
vascular core. It is associated with HPV 6 & 11infection and is most 
commonly seen in children and most common site of origin is inferior 
fornix. It may regress spontaneously.  
 
 
 
 
 
 
 
 
PEDUNCULATED CONJUNCTIVAL PAPILLOMA 
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Sessile papillomas are usually found near the coneoscleral junction 
there is no stalk in this type. It is related to HPV 16 & 18 infection. This 
type is more common adults and there are more chances for dysplastic 
change to take place.  
 
. 
SESSILE CONJUNCTIVAL PAPILLOMA 
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CONJUNCTIVAL - CORNEAL INTRAEPITHELIAL 
NEOPLASIA: 
There are three grades of CCIN based on the level of epithelial 
involvement CCIN grade 1- In this type the tumour cells are limited to 
lower 1/3 of epithelium. 
 
 
 
 
 
 
CCIN grade 2 – in this type the tumour cells are involving upto 2/3 
of the epithelium.  
 
 
 
 
 25 
 
CCIN grade 3-  in this type the full thickness of the epithelium in 
involved by tumour cells. Here the basement membrane is not breached 
by tumour cells. 
                                                    
Conjunctival - corneal intraepithelial neoplasia may be classified into 
three types  
-  papilliform,  
- gelatinous, 
- leukoplakic.  
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GELATINOUS TYPE 
 
 
 
 
 
 
 
Gelatinous is the most common type and it appears as an ill defined 
translucent thickening. There are three varients 
- Circumscribed 
- Nodular and 
- Diffuse type. 
Nodular variant is rapidly growing with a high incidence of 
metastasis.  
Diffuse type is slow growing and it mimics conjunctivitis 
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Both benign and malignant lesions resembles each other thus 
making it difficult to differentiate.  
PAPILLIFORM TYPE 
Papilliform type is a fleshy mass with numerous hyperaemic spots 
over its surface which may match up to the location of fibrovascular core. 
They are clinically benign and they look like a highly vascularised soft 
tissue mass. 
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LEUKOPLAKIC TYPE 
“Leukoplakic type appears as a focal thickening of stratified 
squamous epithelium.The most common site of origin of this type is 
conjunctiva near the limbus. The lesions may have pigmentations and 
pretend to be as malignant melanoma (Shields et al. 2008)”. 
 
 
 
 
 
 
 
Corneal OSSN is most commonly an expansion from conjunctival 
lesions. This type have a greyish white appearance with a well 
demarcated borders and have finger like projections. These lesions are 
usually avascular. They are typically idle, develops very slowly and are 
liable for reappearance. “Isolated corneal involvement has found to be 
very aggressive in rare cases, as the bowman’s layer is resistant to 
invasive lesions (Cha et al. 1993)”.  
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INVASIVE OCULAR SURFACE SQUAMOUS NEOPLASIA 
 
It is characterised by groups of tumour cells that invades stroma by 
breaching  the basement membrane of the conjunctival epithelium. The 
most common route of tumour spread is by local invasion.  
Uveitis, increased intra ocular pressure, detachment of retina and 
globe rupture can occur if it invades intraocularly. Metastasis is 
uncommon. Regional lymphnodes are involved initially among the 
extraocular structures. “There are two forms of cells noticed associated 
with tumour cells Spindle type cells and mucoepidermoid cells”. 
Mucoepidermoid cells are known to spread intra orbitally and prone for 
recurrence.  
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Lesions are usually asymptomatic or may present with irritation, 
redness or visual impairment. Patient may present without any symptoms 
or with unbearable pain, defective vision. 
Mucoepidermoid carcinoma is a uncommon variety of OSSN. It is 
usually noticed in elderly individuals. As it is more aggressive wide 
excision and close follow up is usually necessary. Local recurrence rate 
reported to be about 5% and regional lymph node metastasis at about 
<2%. Aggressive variants like muco-epidermoid carcinoma, spindle cell 
carcinoma and immunocompromised patients have a worst prognosis. 
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DIAGNOSIS AND INVESTIGATIONS 
First the lesion should be assessed clinically to look for 
- Type of lesion, 
-  Dimension,  
- Location,  
- External appearance,  
- Blood vessels  
Intraocular involvement should be assessed by slit lamp 
examination, dilatated fundus examination and gonioscopy.  
 
Lymphatic spread to cervical lymph node group 1 and group 2, 
group 3, 4 and 5 should be examined to look for metastasis . 
 
B scan should be done in patients with opaque media to assess the 
scleral involvement and intraocular spread. Non-invasive techniques like 
UHR OCT and ultrasound biomicroscopy has made it possible to evaluate 
the extent of corneo-scleral invasion in OSSN. 
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ULTRASOUND BIOMICROSCOPY 
Ultrasound biomicroscopes helps in complete imaging of deep 
ocular structures by reflecting high energy sonic waves from inside of the 
eye. An ultrasonic biomicroscope is perfect for glaucoma screening, 
determining lens and cornea pathologies,intra ocular tumours, ocular 
surface lesions or sizing phakic intraocular lenses. Ultrasonic 
biomicroscopes typically operate with frequencies up to 50MHz, with 
detection depths of  8mm or more. 
 
ADVANTAGES 
- High scan penetrance, especially useful for large lesions 
DISADVANTAGES 
- Low resolution,  
- Cannot evaluate epithelial versus subepithelial nature of lesion 
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ANTERIOR SEGMENT OCT 
 
“Anterior segment optical coherence tomography (OCT) allows in 
vivo examination of morphologic and even histological characteristics of  
the tissues”. UHR OCT provides a non-invasive , noncontact and high 
axial resolution imaging for in vivo detection of various anterior segment 
pathologies.  
 
“Anterior segment Ultra High Resolution Optical Coherence 
Tomography (UHR OCT) in ocular surface squamous neoplasia reveals 
epithelial thickening, increased reflectivity of the epithelium, and an 
abrupt demarcation from normal to abnormal tissue”.  
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Typically there is sharp demarcation betweeen the reflectivity of 
normal and diseased epithelium,thus allowing for exact localization of the 
tumour margins. It is also helpful in the delineation of the tumour and to 
detect early subclinical recurrences.  
 
 
CONFOCAL MICROSCOPY 
Confocal microscopy aids in initial clinical evaluation of OSSN, 
treatment , estimation of recurrence  and in patients with OSSN it helps to 
assess the effectiveness of chemotherapeutic drugs. It is able to 
differentiate between various presentations of OSSN. 
ADVANTAGES  
- It can be done as an outpatient procedure, less invasive and there is 
no pain during the procedure.  
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- It is helpful while managing incapacitated elderly individuals or 
patients who doesn’t want to undergo surgery. 
 
-  It can improve the potency of diagnosis as the cytological picture 
obtained can be analysed without delay by pathologist. 
 
- Confocal microscopy is helpful in differentiating invasive tumour 
& carcinoma insitu. 
 
- Assessment of subtypes ,  
- Detect recurrent tumours and 
- Follow-up. 
 
DISADVANTAGES 
 
- Confocal microscopy when compared to UHR OCT provides a 
transverse view without referring to the neighbouring corneal layer.  
 
- Only upto 500µm of depth can be assessed by this method.  
 
CT scans or MRI are used to assess the orbital or anterior eye 
involvement. 
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HISTOPATHOLOGIC EXAMINATION 
The investigation of choice for diagnosing OSSN being tissue 
biopsy from the lesion. Based on the report mode of treatment can be 
planned.     
 
“Small tumours with minimal limbal involvement or  ≤ 15 mm size 
excision and biopsy is ideal. Wedge biopsy is considered for lesions with 
large diameter”. 
 
Microscopic examination of the excised tissue with negative 
margin shows an abrupt transition of the epithelium from the adjacent 
uninvolved normal conjunctival epithelium. Lesion should be studied 
microscopically for architectural and cytological atypia. Both margin and 
base of the lesion should be studied.  
 
Types of dysplastic cells are 
1)  Small cell with high nucleus- cytoplasmic ratio,  
2) Spindle cell bearing oval-shaped nucleus, 
3) Large cell with hyperchromatic nucleus .  
Tumour cells also contains pleomorphic nucleus and high mitotic 
figures.. 
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The histopathologic terms used to describe the Ocular Surface 
Squamous Neoplasia includes (Font et al. 2006) 
 
1) Dysplasia             
  There are three grades of dysplasia based on the intraepithelial 
involvement. PAS staining is used to assess the depth of epithelial 
involvement by detecting glycogen in normal cells.  
“The proliferating cell nuclear antigen (PCNA), Ki-67 and p53 
immunostaining and argyrophillic nucleolar organizer region 
(AgNOR) staining may also be useful for grading the dysplastic 
lesions and to correlate it with clinical and morphological findings 
(Aoki et al. 1998)”. 
 
It can classified into 
a) Mild – < 1/3 of  epithelium is involved by dysplastic cells 
b) Moderate – Atypical cells extends upto the middle third of 
epithelium 
c) Severe  - Entire width of epithelium is involved by dysplastic 
      cells. 
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2) Carcinoma in situ 
    Involvement of entire width of epithelium, with retained 
    Integrity of epithelial basement membrane is known as carcinoma 
in situ. 
 
3) Invasive carcinoma: 
           The basement membrane has been breached by dysplastic cells 
upto the level of substantia propria. Even one cancer cell with 
abnormal nuclei and formation of cancer cell nest is a definitive 
indicator of   invasive  carcinoma. 
 
CYTOLOGY 
 
Cytology is done by two methods  
1) Exfoliative cytology – In this the cells are taken up for study by 
spatula or cytobrush. 
2) Impression cytology- In this the cells are taken by special devices. 
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EXFOLIATIVE TECHNIQUE 
 
In this a cytobrush is used to collect the tumour cells, because there 
is less adhesions between the tumour cells. 
 
ADVANTAGES 
 - Simple technique in diagnosing and patients can be reviewed after 
   management for OSSN. 
- Helpful in detection of recurrences. 
 
DISADVANTAGES 
-  Discomfort for the patient,  
-  Problems with drying artifacts,  
-  Problems with cellular overlap. 
 
IMPRESSION CYTOLOGY 
“Impression cytology is easy and cheap and the association 
between the cells is maintained.but these specimens should be processed 
without any delay. Impression cytology has been widely used as a non- 
invasive method for conjunctival biopsy in cases of suspected Ocular 
Surface Squamous Neoplasia”.  
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“Using CAP for specimen collection, about 80% correlation was 
found between diagnosis from impression cytology and results of 
histopathology specimens obtained from incisional biopsy. IC using 
biopore membrane is highly accurate. In IC cellulose acetate paper with a 
pore size ranging from 0.025 – 0.45 micron or other materials like 
nitrocellulose filters, Biopore membranes, or polyether sulfone filters are 
used and the cells that get adhered to exterior surface of device and was 
taken up for examination”.  
 
ADVANTAGES  
-    Simple and non-invasive procedure for both diagnosing and review of 
     patients.  
-   Relatively easy to collect samples from epithelium, 
 -  Less discomfort for patient,  
-   Suitable to do as a day care procedure,  
-   Exact localisation of the key area, 
-   Association between the cells can be studied. 
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DISADVANTAGES  
 
- It is not suitable for patients having keratotic lesions, as the keratotic 
lesions are more common in OSSN (68%) 
- As IC can study superficial cells alone it very difficult to differentiate 
between CCIN and invasive carcinoma. 
-  If the report came as negative excision biopsy is needed 
 
“At present, no cytologic criteria have been identified that reliably 
differentiate invasive carcinoma from in situ in Impression Cytology 
samples. Squamous cell abnormalities may be classified into 4 groups, 
using a modification of the Bethesda system in cervical 
cytology(Solomon et al.2002)”  
 
-  Atypical squamous cells (ASC)  
-  Low grade squamous intraepithelial lesions (LSIL), includes 
       squamous papilloma & mild dysplasia 
 42 
 
 
 
  
- High grade squamous intraepithelial lesions (HSIL), including 
        moderate to severe dysplasia & carcinoma in situ (CIS). 
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- Squamous cell carcinoma. 
 
 
“One series of OSSN found that SCC from cytology had a highest 
rate of correlation(91.7%) with histology followed by HSILs (45.5%), 
ASCs(42.9%), normal epithelia (33%), and LSILs (21.4%), 
respectively.(Tananuvat et al. 2008)” 
 
“Barros and co workers used a scoring index modified from the 
Bethesda system which revealed a predictive index score of ≥4.5 
represented the best cut-off point for diagnosis of SCC by using IC with a 
sensitivity of 95%, specificity of 93%, positive predictive value of 95%, 
and a negative predictive value of 93%.(Barros et al. 2009)” However, 
the skill and the experience of cytologist are necessary for interpretation 
of the IC specimens. 
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IMMUNOHISTOCHEMICAL ANALYSIS 
 
Number of Ki-67 positive cells in conjunctival SCC and CCIN 
increases from normal to low grade Squamous Intraepithelial lesions to 
high grade Squamous Intraepithelial Lesions. Hence Ki-67 may be used 
as a useful diagnostic indicator for Ocular Surface Neoplasia. 
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TREATMENT 
  
The available treatment options are 
-  Surgery 
 -     Topical chemotherapy  
 -     Cryotherapy 
 -     Topical immunotherapy 
 -     Radiotherapy 
 
“The main strategy in the treatment of OSSN is complete excision 
of the tumor with wide tumour free margin followed by double freeze-
thaw cryotherapy for the conjunctival margin” and “alcohol 
epitheliectomy for the corneal component of the lesion”. When the tumor 
is attached to the globe, a thin strip of sclera should be excised. In every 
patients no touch surgical method  is followed to avoid tumour handling 
which may result in tumour seeding. 
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SURGICAL EXCISION  
 
  Excision allows an immediate histopathological evaluation, 
debulking of the lesion and excludes invasive carcinoma. Special stains 
like Rose Bengal or Lissamine Green can be used to demarcate the 
tumour outline.  
'No-touch' Surgical method : 
It can be performed under local peribulbar or retrobular anesthesia 
by  using a 1:1 mixture of 0.75% bupivacaine and 2% lidocaine. 2.5% 
Phenylephrine drops  are used to cause vasoconstriction, thus reducing 
bleeding perioperatively and allows better visualization of the corneal 
involvement of the tumor. 
The borders of the tumor outlined and 4-mm margins of the tumour 
are marked with the help of calipers at the edge of sclera. Conjunctiva is 
lifted with the help of  forceps and with a pair of Westcott scissors first 
incision is made.  
Initial dissection is limited to the marked margins of the tumour 
and any contact of the tumor with the instruments is better avoided to 
prevent tumor seeding. Once  the dissection of the peripheral marked 
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margins is completed, the dissection is focussed towards the center of the 
lesion. If the tumor gets adhered to the sclera, with the help of  blade and 
forceps a partial thickness sclerectomy is done. The tumour is removed in 
toto and the specimen is sent for histopathological evaluation in formalin. 
Absolute alcohol epitheliectomy is indicated in cases of corneal 
involvement. For better visualization of the corneal involvement.  Slit 
lamp is used to make a careful picture of the lesion. The pupil must be 
dilated to better visualize the corneal involvement during surgery. The 
epithelium that are devitalized is scraped with a blade removing about 3–
4 mm of safety margins similar to that of  conjunctiva. The scraped cells 
are then placed in a cellulose sponge and sent for histopathological 
examination. 
The scleral bed and limbus are also to be scraped, and then the 
conjunctival margins of the lesion and the limbus were frozen, and the 
scleral bed is cauterized. By doing so complete hemostasis is achieved 
and the residual tumor cells are made nonviable. 
 
Tumour should be removed along with 3mm of normal conjunctiva 
is essential.  If the raw area resulting from excision is small then it should 
be corrected by primary suturing and larger gap needs either a 
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transpositoned flap from conjunctiva, autograft from opposite eye, or 
buccal mucosal graft or amniotic membrane graft.  
 
Frozen section is accurate in delineating the horizontal tumor 
spread can be helpful in evaluate the sufficiency of tumour removal. If 
excised margin is positive for tumour cells then the free conjunctival 
edges are excised by 2 mm.  
  
Negative margins will have a recurrence rate which range from 5% 
to 33% to as high as 56% in those where margins were found to be 
positive. Higher recurrence rates were found in more severe grades of 
OSSN. In patients with intraocular spread enucleation is preferred. For 
patients with orbital invasion treatment modality may range from local 
resection of the tumour and or irradiation to orbital exenteration sparing 
the eyelid . 
 
COMPLICATIONS 
 
 Complications of surgical treatment are those resulting from 
healing process particularly in patients with advanced lesions such as 
tissue granulation, pseudopterygium formation, symblepharon, diplopia 
from shortening of tissues, blepharoptosis and limbal stem cell 
deficiency. 
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CRYOTHERAPY 
 
Along with surgical removal cryotherapy is essential and is usually 
done in all cases with OSSN.  
 
MECHANISM OF ACTION 
It causes ischemic necrosis of the tumour tissue by occluding the 
microcirculation and the tumour tissues are freezed.  
 
ADVANTAGES 
Radical surgeries like enucleation and exentration can be avoided 
by this procedure as it can destroy groups of tumour cells and tumour 
cells that are locally invasive.  
 
PROCEDURE 
NO cryoprobe with a diameter of 2.5mm or 5mm is used to form 
an ice ball. The cryoprobe is used under the edges of excised conjunctiva. 
Cryotherapy is usually done by deep freezing the tumous tissues then 
allowing them to thaw slowly. This cycle can be done upto 3 times. Site 
of the tumour determines the time required for cryotherapy. The 
cryoprobe should not be applied for more than three seconds. In all the 
patients with OSSN Corneoscleral junction should be covered by 
cryotherapy.  
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COMPLICATIONS 
The complications  of this technique are sclera and corneal 
thinning, cataract, uveitis, phthisis bulbi and limbal stem cell deficiency. 
The size of the iceball is 0.5 mm for the cornea, 2 mm for conjunctiva 
and 1mm for episclera. 
 
TOPICAL CHEMOTHERAPY 
Topical chemotherapy offers a noninvasive mode of managing the 
ocular surface neoplasia with less importance given to the tumor margin, 
and  it potentially eliminates subclinical lesions.  
 
INDICATIONS 
 1)  Conjunctival lesion of more than two quadrants,  
2)   Tumour with corneal involvement covering the pupillary area, 
3)  Limbal involvementof  > 180 degrees, 
4)  Inadequate tumour margin clearance, 
5)  Patients with severe comorbid condition. 
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Drugs that can be used are,  
1) Mitomycin C (MMC) - most commonly used 
2) 5-fluorouracil 
3) IFN α2B. 
 
These agents can be used alone or as an adjuvant with surgery 
(preoperatively, intraoperatively, and postoperatively) for treatment of 
Ocular Surface Squamous Neoplasia .  
 
ADVANTAGES 
     1)  Highest drug concentration can be achieved locally,  
     2)  No systemic side effects, 
     3)  Stress, trauma, pain & increased cost associated with surgical 
procedure are avoided.  
DISADAVANTAGES 
1) In case of large tumours drug penetration is limited. 
 
2) Prolonged use can cause deleterious effect on the ocular surface 
and nasopharyngeal mucosa.  
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MITOMYCIN C 
 
“The role of Mitomycin C in the treatment of Ocular Surface 
Squamous Neoplasia was first described in 1994 by Frucht-Pery & 
Rozenman”. Topical application of MMC in the management of OSSN 
has gained popularity over the past 16 years, as the “whole eye treatment” 
with MMC offers potential benefits over cryotherapy & excision for the 
treatment of extensive and subclinical cases.  
 
MMC is used preoperatively for chemoreduction, intraoperatively 
and postoperatively to prevent recurrence of tumour. 
 
 Mitomycin C is an alkylating agent isolated from actinobacterium 
Streptomyces Caespitosus. It is an anti-tumour antibiotic with a  
molecular weight of  around 334 daltons. 
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MECHANISM OF ACTION 
1)  It interferes with the cell cycle at G1 and S phase and causes cell 
death by inducing apoptosis and cell necrosis, by inhibiting the 
production of DNA.  
2) Main target for action are fastly replicating cells. 
 It decrease extracellular matrix production, inhibits immigration  of 
fibroblast cell.  
3) It suppresses Cellular RNA and protein synthesis.  
4) Through peroxidation of lipids it causes damage to the DNA and it 
mainly acts under aerobic conditions producing free radicals and 
causing cytotoxicity.  
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ABSORPTION 
Systemic absorption following ocular administration of 
mitomycin c is unknown, but is sought to be of varying magnitudes lower 
than those achieved by administrating intravenously.   
METABOLISM 
It gets cleared from ocular tissue after intraoperative topical 
application and irrigation and the metabolism of MMC occurs in other 
affected tissues. Systemic clearance of Mitomycin C is affected primarily 
by metabolism in liver.  
ELIMINATION 
10% of the applied drug is excreted unchanged in urine.  
 
ADVANTAGES 
1) Effects of local application of MMC can lasts for 8 months to years 
even after termination of the treatment thereby mimicing ionizing 
radiation (cytolmegaly, nucleomegaly, and vacuolation).  
2) Lesion located anywhere in the ocular surface even those on the 
conjunctival fornices can be managed.  
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3)  Prevents new tumour cells originating from other areas of ocular 
surface by destroying subclinical disease. 
  
DOSE 
 “0.02% - 0.04%  given four times per day for 7 days in alternate 
weeks (1 week on and 1 week off), similar to those used in fractionation 
of radiation in treatment of systemic cancers”. 
“ Ando et al21 concluded that 0.04% mitomycin C was relatively non-
toxic to intact corneal epithelium”. 
 
MITOMYCIN C EYE DROPS DOSE PREPARATION  
 
0.02-0.04% Mitomycin eye drops is  prepared by reconstituting it 
with distilled water. 
 
0.02%  MMC EYE DROPS PREPARATION 
  
o 0.5 mg/ml can be achieved by mixing 5 mg vial with 10 ml 
distilled water.  
 
o To a sterile eye dropper bottle 6ml of the diluted solution is 
transferred.  
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- Then 9ml of distilled water is mixed with the above. 
 
- The final solution contains 0.02% of Mitomycin C  
 
0.04%  MMC EYE DROPS PREPARATION 
 - 0.5 mg/ml can be achieved by mixing two 5 mg vials with 10 ml of 
   distilled water.  
 
 - To a sterile eye dropper bottle 12ml of the diluted solution is 
transferred.  
 
 - Then 3ml of distilled water is mixed with the above. 
 
The final solution contains 0.04% of Mitomycin C The 
reconstituted solution can maintain its stability only for 2 days if the 
solution is kept under room temperature and it can maintain its stability 
for two weeks if kept under refrigeration. 
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REASONS FOR INTERMITTENT THERAPY 
1) Slower growing cell are protected from injury as intermittent therapy 
provides time for those cells to recover from damage caused to their 
DNA by the drug. 
2) Decrease in the number of stem cells can be prohibited .  
 
SIDE EFFECTS 
Transient side effects are  
1) local irritation  
2) watering,  
3) photophobia,  
4) conjunctival hyperemia,  
5) allergy,  
6) punctate epithelial erosion,  
7) corneal edema,  
8) pyogenic granuloma,  
9) keratoconjunctivitis  and 
10) Nose bleeds. 
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Long term complications are  
1) punctal stenosis,  
2) limbal stem cell deficiency,  
3) cataract,  
4) persisting keratoconjunctivitis,  
5) scleral thinning,  
6) glaucoma and  
7) uveitis.  
 
 
SCLERAL THINNING 
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PRECAUTION 
  
1) Instruct the Patients and their families to carefully handle the 
medication. 
2)  Pregnant women and young children should avoid direct contact 
with the medication. 
3) Superior and inferior punctum are pluged to reduce absorption of 
MMC systemically.  
4) Patients are educated to close the eyes after the application of 
MMC.  
5) Used bottles should be handed over to biomedical department for 
discarding it safely.  
6) If accidently administered intraocularly, cell death can occur that 
may lead to corneal infarction, ciliary body atrophy and retinal 
infarction. 
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OTHER USES OF MMC 
Current applications include  
1) Pterygium surgery : 
Topical concentrations of  0.02% and 0.04% of Mitomycin C has been 
administered with duration of therapy varying from 5 days to 2 weeks 
post operatively, as it can prevent the recurrence of pterygium. 
2) corneal refractive surgery,  
3) glaucoma surgery: 
Mitomycin C is used in trabeculectomy to reduce scarring, thus it 
helps to prevent closure of the filtration site. It should be reserved 
for the eyes with a high chance of failure or with a failed previous 
conventional filtering surgery. 0.01-0.05% of  Mitomycin C is 
administered intraoperatively as a single topical application for 1-5 
minutes. The outcome of trabeculectomy is improved with the 
application of MMC, which was clearly reported in many studies.  
Complications :  
a) persistent hypotony  
b) Endophthalmitis   
4) Dacryocystorhinostomy surgeries 
5) Allergic eye disease 
6)  Squint surgeries 
7)  Cicatricial eye disease. 
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5 -FLUOROURACIL 
 
When applied as a topical solution it gets metabolised into 5-F 
DUMP and it prevents DNA and RNA formation by acting on 
thymydilate kinase enzyme. It is a cell cycle inhibitor acting on S phase. 
5 flourouracil can be used alone or as an adjuvant to excision or 
debulking therapy.  
DOSE: 
“1% topical solution of 5-FU in cycles of 4 days on followed by 30 
days off till the lesion subsides”.   
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ADVANTAGES 
1) It a stable solution and there is no need for refrigeration.  
2) Fewer side effects, 
3) Not expensive 
4) Easy to handle by medical practitioners and the patients. 
 
SIDE EFFECTS 
Topical 5 flourouracil can cause lid toxicity, epiphora and 
superficial keratitis. 
 
IMMUNOTHERAPY 
 
“Maskin was the first to report the application of topical interferon 
(IFN-α2b) in 1994, for the management of multi-focal limbal OSSN”.  
 
Interferon alpha 2b (INF-α2b) occurs naturally as a glycoprotein. It 
has antiviral and antitumor actions.This drug has a negligible action on 
stem cells. 
 
 DOSE 
“Recombinant topical IFN-α2b 1 million IU/ml 4 times per day 
until there is resolution of lesion and continued for a month thereafter”.  
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INDICATIONS 
1) Reserved for lesions that are not responsive to topical MMC. 
2) For wider and extensive OSSN involving >4 clock hours of the 
limbus. 
3) Recalcitrant, Residual or Multifocal and recurrent lesions, 
4) Leisons involving the visual axis where surgery has a limited role.  
 
SIDE EFFECTS 
1) Topical - Follicular conjunctivitis, conjunctival injections and 
corneal  epithelial  microcyst.  
 
2) Subconjunctival - Transient fever and myalgia.  
 
When compared to Mitomycin C it takes a longer duration for 
complete resolution of the tumour and it is more toxic. 
 
 PEGYLATED INTERFERON ALPHA 2B 
 
It is a derivative of recombinant interferon alpha 2b which was 
developed to decrease the renal clearance of traditional recombinant INFα 
2b. By attaching a single straight-chain polyethylene glycol moiety to 
interferon alpha 2b there is a significant reduction in renal clearance thus 
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increasing plasma half-life of the drug to tenfold, but there is no change 
in volume of distribution or spectrum of activity. 
 Thus the pegylated interferon can be given once weekly for treating 
systemic diseases. 
 
DISADVANTAGE 
PEGIFNa2b is much costlier than non-pegylated interferon.  
 
The surgical resection of OSSN is usually supported by topical 
application of drugs based on size of the lesion. Larger the diameter 
lesion treated by combined modality of treatment proves to be successful. 
 
“Comparing these three drugs in the treatment of noninvasive 
Ocular Surface Squamous Neoplasia reveals that MMC is the most 
effective (88%) in clearing the lesion, 5-FU (87%) and IFNα-2b (80%)”.  
MMC has the highest rate of side effects, as it is the most frequently used 
topical agent. IFNα-2b though is least toxic it is the costliest of the three 
agents.  
 
  
 65 
 
OTHER MODALITIES OF TREATMENT 
1) Plaque brachytherapy with Iodine-125  
2) Immunotherapy with dinitrochlorobenzene (DNCB), 
3) Gamma radiation and Beta-radiation therapy (strontium 90 radiation) 
4)  Urea 
5)  Anti-VEGF 
 6)  Phototherapeutic keratectomy with the excimer laser 
7)  Retinoic acid 
8)  Photodynamic therapy. 
All of these treatment modalities have been used occasionally and 
does not constitute a main treatment options. 
 
Enucleation to be done for intra ocular spread and Exenteration to 
be done for for orbital invasion. 
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PHOTODYNAMIC THERAPY 
- OSSN can be treated with Photodynamic therapy (PDT) .  
- PDT based on the use of verteporfin,   
- It is a light-sensitive dye applied intravenously, 
- It has a high affinity for abnormal blood vessels.  
- When it is exposed to light in the range of 689 or 692 nm, direct cell 
death and immune-mediated destruction of the nearby cells occur. 
-  Barbazetto et al. have used 6 mg/m2 body surface of verteporfin 
injection followed by a light dose of 50 J/cm2 1 min after giving the 
injection.  
- Localized tumor regression has been noted following PDT. 
- It can be combined with other treatment modalities for localised 
conjunctival OSSN.   
 
RECENT ADVANCES 
A potential but as of not tested therapeutic option for the treatment of 
OSSN is “Cetuximab is an anti-epidermal growth factor receptor 
monoclonal antibody. Anti-EGFR agents were originally developed as a 
solid tumour anti-neoplastic therapy just like anti-VEGF antibodies, and 
are currently used in colorectal, non-small cell lung cancer and ovarian 
cancers”. They have also been shown to be effective against Squamous 
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Cell Carcinomas of the head and neck. It is not clear whether epidermal 
growth factor plays a role in the growth or development of OSSN. There 
are several ocular side effects that have been reported resulting from 
systemic administration of anti-EGFR treatment  including 
blepharitis,dysfunctional tear syndrome and trichiasis. 
 
RECURRENCE 
Recurrence rates of Ocular Surface Squamous Neoplasia varies from 12-
50%. It occurs usually within the first two years of surgery and are most 
common in patients with positive tumour margins.  
Factors predisposing to recurrence of the lesion includes 
1. positive surgical margin,  
2. old age,  
3. large diameter lesions,  
4. high proliferation index (Ki-67 score) and  
5. corneal location.  
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TREATMENT PLAN FOR OSSN < 3 CLOCK HOUR 
 
 
 
 
 
 
 
  
less than three clock 
hours ossn
margin is positive
chemotherapy with 
mitomycin c, then 3 
monthly review and 
follow up every 6 months
if tumour margin 
negative
3 monthly follow up for 1 
year and then every 6 
monthly follow up
excision and biopsy
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ALGORITHM FOR THREE-SIX CLOCK HRS OSSN 
TREATMENT 
 
 
  
 
 
 
 
 
3- 6clock hours 
lesion
If tumour is pre 
invasive
start MMC, monthly 
follow up, quaterly 
evaluation of tumour 
regression, 6 monthly 
review
If tumour is 
invasive
MMC for 
chemoreduction, surgical 
excision with cryo therapy 
with AMG, monthly review 
with quaterly evaluation to 
rule out recurrence, then 3 
monthly review
Biopsy to evaluate 
the invasion 
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ALGORITHM FOR MANAGEMENT OF OSSN >6 CLOCK 
HOURS 
 
 
 
 
 
 
 
> 6 clock hrs 
ossn
if preinvasive
start MMC monthly 
followup,quarterly 
evaluation of tr 
resolution
if complete 
resolution followup 
every 6 months
if invasive 
start high dose 
mitomycin c
total regression
review every month 
upto one year,
then every 3 months
incomplete 
regression
chemotherapy then sx removal 
with cryotherapy and 
AMG,monthly followup then 
followup every 3 months 
if >6 clock hrs after mmc 
palliative radiotherapy
biopsy
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DIFFERENTIAL DIAGNOSIS OF OSSN  
 Pterygium 
 Pannus 
 Pseudoepitheliomatous hyperplasia 
 Vitamin A deficiency 
 Actinic disease 
 Benign intraepithelial dyskeratosis 
 Pinguecula 
 Keratoacanthoma 
 Malignant melanoma and nevi 
 Pyogenic granuloma 
 Dyskeratosis 
 Conjunctival lymphoma (salmon patch)  
 
 
  
 
 
 
 
 
 
 
 
 
PART 2 
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AIM 
 
To study the role of Mitomycin c in the management of Ocular 
Surface Squamous Neoplasia.  
 
PRIMARY OBJECTIVE 
 
To evaluate the role of Mitomycin C as an adjuvant therapy 
intraoperatively and post operatively in the management of Ocular 
Surface Squamous Neoplasia. 
 
SECONDARY OBJECTIVE 
 
To determine the role of Mitomycin C in the prevention of 
recurrence of Ocular Surface Squamous Neoplasia. 
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MATERIALS AND METHODS 
 
The study was conducted at Regional Institute of Ophthalmology, 
Government Ophthalmic Hospital, Chennai.  
20 Patients with histopathologically proven Ocular Surface Squamous 
Neoplasia were registered for this study. 
 
INCLUSION CRITERIA 
 
1. Patients in age group of 40 and above. 
2. Histopathologically proven limbal OSSN with or without corneal  
    Involvement. 
3.Primary and recurrent OSSN. 
 
EXCLUSION CRITERIA 
1. Patients aged less than 40 yrs. 
2. Patients with scleral involvement. 
3. Patients with intraocular and orbital involvement. 
4. Patients with other ocular diseases like limbal stem cell    
   deficiency, ocular surface disorders, intraocular tumours. 
5. Patients with any other systemic illness. 
6. Patients with HIV and other immunocompromised diseases. 
7. Pregnant women. 
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PREOPERATIVE ASSESMENT 
 
Preoperatively detailed history was taken from all the patients, 
general examination was done, uncorrected and corrected visual acuity 
were recorded in all the cases. Slit lamp examination was performed and 
careful assessment of the morphology, site, size shape and colour of the 
lesion, extent of the lesion, corneal involvement was made along with 
routine examination of the ocular adnexa and anterior segment. Fundus 
examination and gonioscopy was done.  
 
A baseline IOP measurement was done in all the cases using 
applanation tonometry. Investigations like complete blood count, random 
blood sugar, urine routine, bleeding time, clotting time, HIV serology was 
done. ultrasound biomicroscopy(UBM) and B scan was done in all the 
cases.  
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SURGICAL PROCEDURE 
Under strict aseptic precautions, under peribulbar block, the 
tumour was surgically removed in toto along with 3-4mm of uninvolved 
conjunctiva. 0.4mg/ml of Mitomycin C applied over the excised site for 
3-4 minutes and then washed with saline. According to the size of the 
defect in the conjunctiva the surgical site is closed by primary suturing of 
the conjunctiva or by grafting. 
 
POSTOPERATIVE CARE AND FOLLOW UP 
Postoperatively 2 cycles of 0.04% Mitomycin C eye drops 4 times 
per day was given approximately for 2 weeks after surgical excision, each 
cycle lasting for 1 week with off period of 1 week in between. All the 
patients were given topical steroids and lubricants throughout the post op 
period. Patients were instructed to come for follow up one month 
following surgery then on third month, sixth month and one year.  
 
 
 
 
 
 
                 
 76 
 
ANALYSIS AND RESULTS 
 
AGE DISTRIBUTION 
AGE GROUP      NO. OF PATIENTS        PERCENTAGE 
40-50 4 20% 
51-60 10 50% 
61-70 6 30% 
Total 20 100% 
 
 
 
 
 
 
20%
50%
30%
AGE DISTRIBUTION
40-50
51-60
61-70
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SEX DISTRIBUTION 
 
SEX NO. OF PATIENTS PERCENTAGE 
MALE 12 60% 
FEMALE 8 40% 
TOTAL 20 100% 
 
 
 
 
 
 
 
60%
40%
SEX DISTRIBUTION
MALE
FEMALE 
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LATERALITY 
 
EYE AFFECTED NO. OF PATIENTS PERCENTAGE 
RIGHT EYE 12 60% 
LEFT EYE 8 40% 
TOTAL 20 100% 
 
 
 
 
 
60%
40%
EYE AFFECTED
RIGHT EYE
LEFT EYE 
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TYPE OF THE LESION 
 
TYPE OF LESION NO OF PATIENTS PERCENTAGE 
GELATINOUS 10 50% 
PAPILLOMATOUS 7 35% 
LEUKOPLAKIC 3 15% 
TOTAL 20 100% 
 
 
 
 
 
 
50%
35%
15%
TYPE OF LESION
GELATINOUS      
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SIZE OF THE LESION 
 
SIZE OF THE 
LESION 
NO OF PATIENTS PERCENTAGE 
4mm 1 5% 
5mm 3 15% 
6mm 7 35% 
7mm 5 25% 
8mm 2 10% 
9mm 1 5% 
>10mm 1 5% 
TOTAL 20 100% 
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PRESENTATION OF THE PATIENT 
 
PRESENTATION NO OF PATIENTS PERCENTAGE 
PRIMARY 18 90% 
RECURRENCE 2 10% 
TOTAL 20 100% 
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INDICATION FOR SURGERY 
 
INDICATION NO OF PATIENTS PERCENTAGE 
OCULAR IRRITATION 13 65% 
VISUAL IMPAIRMENT 6 30% 
COSMETIC 
DISFIGUREMENT 
1 5% 
TOTAL 20 100% 
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CORNEAL INVOLVEMENT 
 
CORNEAL 
INVOLVEMENT 
NO OF PATIENTS PERCENTAGE 
INVOLVED 18 90% 
NOT INVOLVED 2 10% 
TOTAL 20 100% 
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RECURRENCE RATE 
 
RECURRENCE 
RATE NO OF PATIENTS PERCENTAGE 
RECURRENCE 1 5% 
NO RECURRENCE 19 95% 
TOTAL 20 100% 
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TIME OF RECURRENCE 
 
 
 
 
 
 
0%
1%
2%
3%
4%
5%
6%
0-1 month 1-3 month 3-6 month 6month-1 
year
Time of recurrence
TIME OF 
RECURRENCE 
NO OF PATIENTS PERCENTAGE 
0-1 MONTH NIL 0% 
1-3 MONTHS NIL 0% 
3-6 MONTHS NIL 0% 
6 MONTHS- 1 YEAR 1 5% 
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POST OPERATIVE FOLLOW UP 6- 12 MONTH 
 
 
 
 
In the study group with Ocular Surface Squamous Neoplasia who 
received intraoperative and post operative Mitomycin C on one year 
follow up recurrence developed only in 5% of patients and the remaining 
95% does not had any recurrence. By chi square test it is statistically 
significant. P value < 0.001** 
 
 
 
 
 OBSERVED N PERCENTAGE P VALUE 
RECURRENCE 1 5 
<0.001** 
NOT 
RECURRENCE 
19 95 
TOTAL 20 100 
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AGE AND RECURRENCE 
AGE GROUP NO OF PATIENTS PERCENTAGE 
40-50 NIL 0% 
51-60 NIL 0% 
61-70 1 5% 
 
AGE AND RECURRENCE 
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COMPLICATIONS FOLLOWING MMC 
 
 
 
 
5%
5%
90%
COMPLICATIONS
ALLERGIC CONJUNCTIVITIS
PUNCTATE EROSION
NIL COMPLICATIONS
COMPLICATIONS NO OF PATIENTS PERCENTAGE 
ALLERGIC 
CONJUNCTIVITIS 
1 5% 
PUNCTATE 
EROSION 
1 5% 
NIL 
COMPLICATIONS 
18 90% 
TOTAL 20 100% 
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SIZE AND RECURRENCE 
 
SIZE OF 
LESION 
NO. 
PATIENTS 
RECURRENCE PERCENTAGE 
4mm 1 Nil 0% 
5mm 3 Nil 0% 
6mm 7 Nil 0% 
7mm 5 Nil 0% 
8mm 2 Nil 0% 
9mm 1 Nil 0% 
10mm 1 1 5% 
Total  20 1 5% 
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DISCUSSION 
Surgical excision is the main modality of treatment for OSSN. 
Clinical examination and impression cytology are not effective in 
diagnosing invasive lesions, hence surgical excision becomes the first 
step in the management of OSSN. Advantages of surgical excision are a 
bulk of tumour can be removed, immediate microscopic examination of 
the tissue is possible, presence of invasive disease can be ruled out. The 
main drawback of surgical excision is high recurrence rate. So several 
other treatment modalities are used intraoperatively and postoperatively 
to reduce the rate of recurrence. 
 
Intraoperative adjunctive treatments include cryotherapy, 
mitomycin c application, alcohol keratectomy and lamellar 
sclerokeratectomy. postoperative adjunctive treatments include – 
chemotherapy by using anti metabolites ( MMC, 5-fluorocil), β 
irradiation, topical urea and immunotherapy (IFN α-2B, 
dinitrochlorobenzene).  
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The residual tumour cells along the margins of surgical excision 
were destroyed by using intraoperative cryotherapy. Thereby it can 
decreases the recurrence and hence it is most commonly used along with 
primary surgical excision. “The overall recurrence does not change 
significantly between those patients treated with intraoperative 
cryotherapy and those did not received cryotherapy (Br J Ophthalmol 
2004; 88:17–18)”. 
 
Intraoperative and post operative topical Mitomycin C as an 
adjunctive to surgical excision have many advantages in those patients 
with diffuse type of lesion and in those with recurrence. This drug has a 
significant anti-tumour activity and has a selective action on fastly 
replicating tumour cells.  
 
Lesion located anywhere in the ocular surface even those on the 
conjunctival fornices can be managed effectively with MMC. It can 
prevent new tumour cells originating from other areas of ocular surface 
by destroying subclinical disease. 
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Mitomycin C has a long lasting effect even after completion of 
treatment thus reducing the potential for local metastatic spread .The bare 
surface created by surgery can be closed with the adjacent conjunctival 
tissues after Mitomycin c application, and it may be effective in 
eliminating residual tumour cells in the conjunctiva following surgical 
excision. 
 
“Since 1994 several studies have reported the role of MMC in the 
treatment of both primary and recurrent OSSN”.  
 
Mitomycin C should not be used alone and it should be combined 
with surgical excision as the invasive tumours may go unnoticed and this 
drug may have a limited penetrance into the deeper tumour tissues.  
 
“Complications of Mitomycin C are common but are largely 
confined to the ocular surface. Self-limiting short-term complications 
were common however, deficiency of limbal stem cell appears to be a 
significant long-term complication (Br J Ophthalmol 2010; 94:1316-
1321)”. 
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One of the patient in this study developed punctuate corneal 
erosion and another patient in this study developed allergic conjunctivitis. 
Those patients in our study does not show severe side effects like scleral 
thinning, cataract and iritis. This is due to intermittent therapy as the 
slower growing cell are protected from injury and it provides time for 
those cells to recover from damage caused to their DNA by the drug and 
decrease in the number of stem cells can also be prohibited .  
 
Thus when contemplating use of topical Mitomycin C these serious 
complications should be taken into consideration. Serious side effects due 
to this drug can be acceptable when compared to beneficial effects if this 
drug. 
 
“Our study demonstrates the use of intra operative and post 
operative Mitomycin C reduces the recurrence rate of OSSN and should 
be considered as an adjuvant treatment modality along with surgical 
excision”.  
 
There is a significant reduction in the recurrence rate of Ocular 
Surface Squamous Neoplasia following two courses of Mitomycin C.  
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“These properties of mitomycin C support its potential 
chemotherapeutic effectiveness, as an adjunct to surgical excision”. 
 
 “We also noted that there are no systemic complications following 
the use of    Mitomycin C”. 
 
About 95% patients in this study does not developed any 
recurrence on one year follow up period. 5% of patients developed 
recurrence that may be attributed to old age and large diameter lesion. It 
is not possible to strongly believe that the tumour will not recur even after 
following up of the patients for a prolonged period of time.  
 
“But close ongoing follow-up is recommended in view of the 
significant risk of persistent or recurrent disease”. 
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REVIEW OF LITERATURE 
“A study was perfomed by C Chen, D Louis, T Dodd, J Muecke 
between 1998-2003(Br J Ophthalmol 2004; 88:17–18). In this study 
intraoperative mitomycin c was not given. Topical mitomycin c was 
given only postoperatively. 26 patients with hitologically proved non 
invasive limbal primary ossn in 27 eyes, with corneal involvement of  < 4 
clock hours extent was taken for this study. All the lesions were 
surgically excised completely. All cases received two 1 week courses of 
Mitomycin C 0.04% drops four times per day. All the patients were 
reviewed at 6 monthly intervals for 2 years. None of the patients showed 
recurrence. They concluded that topical Mitomycin C after surgical 
excision reduces the recurrence of OSSN and hence it can be considered 
as an adjuvant therapy in the management of OSSN”. 
 
“A similar study was conducted by E G Kemp, A N Harnett, S 
Chatterjee between May 1998 and April 2000(Br J Ophthalmol 
2002;86:31–34) comprising of 11 patients. In this study pre operative and 
intra operative mitomycin c was given. All the 11 patients received 
topical Mitomycin C adjuvant therapy as 0.04% eye drops in two weekly 
courses four times a day either preoperatively alone or also intra 
operatively. All patients showed a positive response in the form of 
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decreased growth or regression in size of the lesion and no serious 
complication. Postoperative follow up of these patients for 6 months to 3 
years after surgery showed no evidence of recurrence in all the patients. 
Thus they concluded that adjunctive therapy with mitomycin C for 
recurrent or diffuse OSSN was well acceptable and showed a good 
outcome”. 
 
“A retrospective study conducted in 2010 (Br J Ophthalmol 2010; 
94:1316e1321) a 10-year review of the treatment outcomes and 
complications of topical mitomycin C in the treatment of OSSN. Of all 
the cases treated short-term complications occurred in 52% of the 
patients, of which only 7% of cases required cessation of treatment. 
Long-term complications like persistent keratoconjunctivitis, corneal 
problems and epiphora occurred in 31% of cases. Most important long-
term complication is deficiency of limbal stem cells occurring in 12% 
cases. Self-limiting short-term complications were common. The results 
thus substantiate the success of Mitomycin C therapy in the treatment of 
OSSN”. 
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“In this study 90 patients with primary/recurrent lesions are taken 
up for the study (Br.j.ophthalmology 2010; 94:555-558). All the cases 
were treated by surgical excision ± cryotherapy, followed by 2 or 3 
courses of topical Mitomycin C post operatively. 73 cases of localised 
non-invasive conjunctival corneal intraepithelial neoplasia and 8 cases of 
recurrent conjunctival corneal intraepithelial neoplasia were managed by 
surgical excision with or without cryotherapy along with post operative 
Mitomycin C. 10 cases in the study group with diffuse conjunctival 
corneal intraepithelial neoplasia managed by Mitomycin C alone. Follow-
up of these patients showed no recurrences (0%) in the localised primary 
group and two recurrences (30%) and one persistent case in the diffuse 
primary group. One case of recurrence (12.5%) in the recurrent group, but 
that was in the eye with a diffuse lesion. They concluded that topical 
Mitomycin C application after surgery reduce the recurrence of  localized 
lesions and can be used as an adjunctive therapy in the management of 
OSSN. Mitomycin C can be used alone in the management of large 
lesions but periodic review is necessary as there is a significant risk of 
persistent or recurrent disease. 
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“C.S. SIGANOS ET AL  in this study eight cases of OSSN were 
included. All of them received 0.02% of intraoperative MMC. Two of 
these patients received conjunctival limbal autograft during surgery. 
Seven patients does not showed any recurrence during follow up and only 
one patient with histologically proved squamous cell carcinoma showed 
recurrence and this patient was treated by topical Mitomycin C and on 
subsequent follow up he did not show any recurrence. Hence it was 
proved that surgical excision combined with Mitomycin c application 
reduces recurrence. It was also concluded that limbal autografting along 
with Mitomycin C does not alter the outcome.”   
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SUMMARY 
 
In this study of 20 patients with Ocular Surface Squamous 
Neoplasia, 50% of patients were in the age group of 51-60 years. 60% of 
patients in this study group are Men and 5% of patients had gelatinous 
type of lesion. Right eye is affected in 60% of patients. Primary OSSN 
occurs in 90% of patients. The commonest indication for surgery is ocular 
irritation (65%). Only 5% of the patients developed recurrence after 
intraoperative and post operative Mitomycin C application. Recurrence 
developed in the age group of about 70 years, and patients with lesion of 
more than 10mm size. 2 patients developed self limiting complications 
like allergic conjunctivitis and punctuate corneal erosion. None of them 
developed serious and long term side effects.  
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CONCLUSION 
The results confirms that introperative and post operative Mitomycin C 
application is the most effective adjuvant therapy in the management of 
ocular surface squamous neoplasia 
The advantages of Mitomycin C over other adjuvant therapies are  
1) The recurrence rate following intraoperative and postoperative 
Mitomycin C is significantly lower than other modalities of 
adjuvant therapy 
2) It mimics ionizing radiation  because its effects can persists for 
many years even after cessation of treatment 
3) By destroying the subclinical disease it prevents the formation of 
recurrence in the ocular surface including the conjuctival fornices 
Short term complications following the treatment are common but self 
limiting, serious complications are avoided by intermittent therapy . 
There are no systemic side effects. 
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PROFORMA 
 
NAME                      :                                                                          
AGE                          :                                                                          
SEX                           :                                                                        
OCCUPATION         :  
ADDRESS                :                                                                        
DATE                        :   
IP NUMBER             :                                                              
DOA                          : 
DOS                           : 
DOD                          : 
COMPLAINTS        : 
PRESENT HISTORY: 
PAST HISTORY        :  
PERSONAL H/O      : 
                     
  
 
GENERAL EXAMINATION 
EXAMINATION OF THE EYES  RE    LE                                         
VISUAL ACUITY                               : 
SLITLAMP EXAMINATION       RE    LE    
LIDS                                                    : 
OCULAR MOVEMENTS                   : 
CONJUNCTIVA                                 : 
CORNEA                                             : 
EXAMINATION OF THE LESION 
 MORPHOLOGY OF THE LESION : 
                        SITE   : 
                        SIZE   : 
                    SHAPE   : 
                  COLOUR   :         
                  SURFACE   : 
                  EXTENT   : 
 IRIS      : 
  
 
ANTERIOR CHAMBER  : 
PUPILS     : 
LENS     : 
FUNDUS                                              
                                                INVESTIGATIONS 
RE                          LE                  
SYRINGING OF NASOLACRIMAL  DUCT 
SCHIRMER’S TEST 
INTRAOCULAR PRESSURE 
GONIOSCOPY 
B SCAN 
UBM  
COMPLETE   BLOOD COUNT : 
BLEEDING TIME   : 
CLOTTING TIME   :                                                      
RANDOM BLOOD SUGAR  : 
URINE             albumin &sugar  :  
  
 
HIV SEROLOGY    :                                     
BLOOD PRESSURE   :                                                   
SURGERY PERFORMED  : 
DONE ON     :  
POST OPERATIVE TREATMENT   : 
DATE OF MITOMYCIN EYE DROPS STARTED POST 
OPERATIVELY                                                        
HISTOPATHOLOGICAL REPORT : 
FOLLOW UP 
AT EACH VISIT – 
                   VISUAL ACUITY 
                  SLIT LAMP EXAMINATION OF THE EXCISED SITE 
1 MONTH   : 
3 MONTHS   : 
6 MONTHS   : 
1 YEAR   :
  
 
 
MASTER CHART 
1 2 3 4 5 6 7 8 9 10 11                  12          13 
 a b c d 
1. Sherifabee 65/f 41951 RE G 8mm P VI RE a  NR NR NR NR  
2. Subramani 45/m 58888 RE P 6mm P OI RE a  NR NR NR NR  
3. Mani 55/m 68875 RE P 7mm P VI RE a  NR NR NR NR  
4. Nagammal 45/f 57667 RE P 6mm P OI RE a  NR NR NR NR  
5. Kalyani 70/f 70202 RE L 7mm P OI RE a  NR NR NR NR  
6. Rathinavelu 70/m 26130 RE G 11mm P VI RE a  
 
NR NR NR R  
7. Arunachalam 45/m 65536 RE G 5mm P OI RE a  NR NR NR NR  
8. Sumathy 50/f 74754 RE G 9mm P VI RE a  NR NR NR NR  
9. Umaiyal 60/f 75126 LE L 5mm  P OI LE b 
 
 NR NR NR NR  
10. Vellatchi 55/f 73216 LE G 7mm P OI LE a  NR NR NR NR  
  
 
11. Saroja 57/F 62835 RE G 6mm P OI RE a  NR NR NR NR Allergic 
conjuctivitis 
12. Palani 63/m 68653 LE P 6mm P OI LE a  NR NR NR NR  
13. Veeran 54/m 25321 LE P 6mm P CD LE a  NR 
 
NR NR NR  
14. Ravi 55/m 42168 LE P 7mm P OI LE a  NR NR NR NR  
15. Muniammal 57/f 28321 RE G 5mm P OI RE a  NR NR NR NR  
16. Ramadoss 58/m 56234 LE G 8mm P VI LE a  NR NR NR NR  
17. Manickavelu 62/m 74638 LE G 4mm R OI LE b  NR NR NR NR  
18. Indiran 63/m 57271 RE L 6mm P OI RE a  NR NR NR NR Punctate 
erosion 
19. Ramamoorthy 59/m 42675 LE G 7mm R VI LE a  NR NR NR NR  
20. Prakasam 57/m 26832 RE P 6mm P OI RE a  NR NR NR NR  
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KEY TO MASTER CHART 
1)Serial number 
2)Name of the patient 
3)Age & Sex 
4)Op/Ip number 
5)Eye affected 
6)Type of the lesion 
G-Gelatinous type, P-Papillomatous,L-Leukoplakic 
 7)Size of the lesion 
8)Presentation of the patient 
P-Primary,R-Recurrent 
9)Indication for surgery 
OI-Ocular irritation,VI-Visual impairment,CD-Cosmetic disfigurement 
10)Eye operated  
11)Corneal involvement 
a-corneal involved,b-not involved  
 
2 
 
 
12)Post operative follow up 
a-monthly,b-3 months,c-6 months,d-1 year 
NR-No recurrence,R-Recurrence 
 13)Complications   of  Mitomycin c  
 
 
